Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- hsCRP Levels Will Be Cardiovascular Risk Predictor: Takeda’s Post-Hoc Analysis from EXAMINE Study
September 21, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in HBV Carriers Too: PIII Sub-Analysis
September 20, 2017
- Opdivo Gets Label Expansion for Melanoma in South Korea
September 20, 2017
- NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors
September 20, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Daiichi Sankyo Links Up with MD Anderson on AML Therapies
September 19, 2017
- Aptiom Gets FDA Pediatric Nod for Partial-Onset Seizures
September 19, 2017
- Xtandi Delivers Strong Data for Non-Metastatic CRPC in a Boon for Label Expansion Overseas: Astellas
September 15, 2017
- Pralia Jumps in July GP Recollection Ranking on Indication Addition: Anterio
September 15, 2017
- Chugai’s On-the-Spot ADR Info Provisioning Tools Well Received by Physicians, Spreading to Other Makers
September 15, 2017
- Shionogi to File Sakigake-Designated Flu Drug by Year-End Based on PIII Results
September 15, 2017
- NeuroDerm Shareholders OK Acquisition by Mitsubishi Tanabe
September 14, 2017
- FDA Accepts sNDA for Mirabegron Combo Therapy: Astellas
September 14, 2017
- With Canalia Debut as Catalyst, Mitsubishi Tanabe Set to Maximize 3 Diabetes Meds
September 13, 2017
- DS-8201 Data Out for Multiple HER2-Expressing Tumors: Daiichi Sankyo
September 13, 2017
- Linzess Filed for Add’l Indication of Chronic Constipation: Astellas
September 12, 2017
- Tumor Regression Seen in 93% of RCC Patients on Lenvima-Keytruda Combo
September 12, 2017
- Lenvima Stalls QOL Lowering in HCC Patients: Eisai
September 12, 2017
- Chugai Sues Nippon Kayaku over Herceptin Patent
September 11, 2017
- Eisai, Ono to Collaborate on Lenvima-Opdivo Combo in HCC
September 11, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…